Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis

Clicks: 262
ID: 269202
2008
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
We demonstrated that intranasal granulocyte-macrophage colony-stimulating factor given to immunosuppressed mice infected with pulmonary aspergillosis resulted in a sixfold reduction in the lung fungal burden compared to the result for saline-treated mice (P = 0.045). These data suggest that lung-tar …
Reference Key
g2008antimicrobialintranasal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Quezada G;Koshkina NV;Zweidler-McKay P;Zhou Z;Kontoyiannis DP;Kleinerman ES;;
Journal Antimicrobial agents and chemotherapy
Year 2008
DOI
DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/17984233
Keywords
Administration National Center for Biotechnology Information NCBI NLM MEDLINE Mice animals humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't female Disease Models animal* cyclophosphamide / administration & dosage intranasal immunocompromised host* aspergillosis / microbiology lung diseases immunosuppressive agents / administration & dosage aspergillosis / drug therapy* pmid:17984233 pmc2224773 doi:10.1128/aac.00760-07 gerardo quezada nadezhda v koshkina eugenie s kleinerman aspergillus fumigatus / drug effects* granulocyte-macrophage colony-stimulating factor / administration & dosage* fungal* / drug therapy fungal* / microbiology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.